T-cell oncogene rhombotin-2 interacts with retinoblastoma-binding protein 2

被引:0
|
作者
Shifeng Mao
Geoffrey AM Neale
Rakesh M Goorha
机构
[1] St Jude Children's Research Hospital,Departments of Virology and Molecular Biology
[2] University of Tennessee,Department of Pathology
[3] Memphis Tennessee,undefined
来源
Oncogene | 1997年 / 14卷
关键词
oncogene; rhombotin-2; RBP2; transcription;
D O I
暂无
中图分类号
学科分类号
摘要
The LIM domain protein rhombotin-2 (RBTN-2/TTG-2/Lmo2) has distinct functions in erythropoiesis and in T-cell leukemogenesis. Additional functions for RBTN2 are indicated by its expression in non-hematopoietic tissues. These diverse functions of RBTN2 are presumed to be accomplished through physical interaction with different protein partners that bind the LIM domains of RBTN2. To identify these proteins which may modulate the activity of RBTN2, a human cDNA library was screened using the yeast two-hybrid assay. Using the RBTN2 LIM domain region as `bait', the retinoblastoma-binding protein 2 (RBP2) was identified as a partner for RBTN2. The interaction between RBTN2 and RBP2 was confirmed using in vitro binding assays, and by co-immunoprecipitation of the two proteins. Deletion analysis showed the second LIM domain of RBTN2 was necessary and sufficient for binding to the last 69 amino acids of RBP2. The interaction between RBTN2 and RBP2 had a functional consequence: the combination of RBP2 and RBTN2 gave higher transcription in vitro, than RBTN2 alone. The interaction with RBP2 suggests two additional functions for RBTN2: (i) RBTN2 may directly affect the activity of RBP2, and/or (ii) RBTN2 may indirectly modulate the functions of the retinoblastoma protein by binding to RBP2.
引用
收藏
页码:1531 / 1539
页数:8
相关论文
共 50 条
  • [41] The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation
    Hill, RJ
    Zozulya, S
    Lu, YL
    Ward, K
    Gishizky, M
    Jallal, B
    EXPERIMENTAL HEMATOLOGY, 2002, 30 (03) : 237 - 244
  • [42] CHARACTERIZATION OF ALPHA-2-IFN BINDING AND POST BINDING ON HUMAN T-CELL LINES
    COLLINS, TJ
    EVANS, SS
    MAYERS, GL
    FASEB JOURNAL, 1988, 2 (06): : A1649 - A1649
  • [43] T-CELL ACTIVATION - 2-FOR-T
    GUERDER, S
    FLAVELL, RA
    CURRENT BIOLOGY, 1995, 5 (08) : 866 - 868
  • [44] The T-Cell Oncogene Tal2 Is a Target of PU.1 and Upregulated during Osteoclastogenesis
    Courtial, Nadine
    Muecke, Christian
    Herkt, Stefanie
    Kolodziej, Stephan
    Hussong, Helge
    Lausen, Joern
    PLOS ONE, 2013, 8 (09):
  • [45] A 2ND SITE ON THE CYTOCHROME-C T-CELL DETERMINANT THAT INTERACTS WITH THE IA MOLECULE
    FOX, BS
    CARBONE, F
    PATERSON, Y
    RONCHESE, F
    GERMAIN, RN
    SCHWARTZ, RH
    FEDERATION PROCEEDINGS, 1987, 46 (03) : 1046 - 1046
  • [46] A 2ND SITE ON THE CYTOCHROME-C T-CELL DETERMINANT THAT INTERACTS WITH THE IA MOLECULE
    FOX, BS
    CARBONE, F
    PATERSON, Y
    RONCHESE, F
    GERMAIN, RN
    SCHWARTZ, RH
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1987, : 287 - 287
  • [47] 2 PATHWAYS OF T-CELL HELP MEDIATED BY DIFFERENT T-CELL SUBSETS
    COFFMAN, R
    SEYMOUR, B
    MOSMANN, T
    FASEB JOURNAL, 1988, 2 (05): : A1444 - A1444
  • [48] Acquired Senescent T-Cell phenotype Correlates With Clinical Serverity in GATA Binding Protein 2-Deficient Patients
    Ruiz-Garcia, Raquel
    Rodriguez-Vigil, Carmen
    Manuel Marco, Francisco
    Gallego-Bustos, Fernando
    Jose Castro-Panete, Maria
    Diez-Alonso, Laura
    Munoz-Ruiz, Carlos
    Ruiz-Contreras, Jesus
    Paz-Artal, Estela
    Ignacio Gonzalez-Granado, Luis
    Miguel Allende, Luis
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [49] Interplay of T-cell receptor and interleukin-2 signalling in Vγ2Vδ2 T-cell cytotoxicity
    Li, Haishan
    Pauza, C. David
    IMMUNOLOGY, 2011, 132 (01) : 96 - 103
  • [50] THE TTG-2/RBTN2 T-CELL ONCOGENE ENCODES 2 ALTERNATIVE TRANSCRIPTS FROM 2 PROMOTERS - THE DISTAL PROMOTER IS REMOVED BY MOST 11P13 TRANSLOCATIONS IN ACUTE T-CELL LEUKEMIAS (T-ALL)
    ROYERPOKORA, B
    ROGERS, M
    ZHU, TH
    SCHNEIDER, S
    LOOS, U
    BOLITZ, U
    ONCOGENE, 1995, 10 (07) : 1353 - 1360